We recently published a list of 10 Stocks Are Dominating Like Wall Street Titans. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against ...

Recursion Pharmaceuticals, Inc.'s stock (NASDAQ:RXRX) has slid 57% since my last look in February. Despite the company leveraging artificial intelligence in drug discovery, I was “unconvinced ...

Shares in Recursion fell by 13.4% on 5 May, dropping from $5.49 at market open to $4.76 at close following the pipeline restructuring announcement. The terminated programmes include REC-2282, REC ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were sinking 8.2% lower as of 10:57 a.m. ET on Monday. The clinical-stage ...

Altitude Lab, a biotech accelerator formed by Recursion, on Wednesday announced the launch of a pre-seed venture fund to support early-stage startups affected by the changes in federal funding policy.

Learn how to choose between recursion and iteration for traversing and manipulating composite structures, such as trees, graphs, or nested lists. Sign in to view more content ...

Recursion saw no improvements on patient-reported outcomes (PROs), or physician-led measures, after 12 months of treatment. Talking on an earnings call in August, Najat Khan, Ph.D., chief R&D ...

Recursion finished Q2 2024 with a net loss of $97.5 million, up from a net loss of $76.7 million in the year-ago quarter, on revenue of $14.4 million, up 31% from $11.0 million in Q2 2023.

After a tough year, Exscientia will merge into Recursion, creating one company that has 10 clinical readouts expected over the next 18 months. After a year defined by pipeline cuts, ...